<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876237</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-A-2014-04</org_study_id>
    <secondary_id>2014-A00300-47</secondary_id>
    <nct_id>NCT02876237</nct_id>
  </id_info>
  <brief_title>Geriatric Determinants of General Repercussion of Radiotherapy for Patient Over 75 Years With Prostate Cancer</brief_title>
  <acronym>PROGERAD</acronym>
  <official_title>Patient Over 75 Years With Prostate Cancer: Geriatric Determinants of General Repercussion of Radiotherapy With Curative Intent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to carry out a prospective analysis of physical impact,
      psychological, cognitive and social of radiotherapy in all patients over 75 years bearer of
      localized prostate cancer with an indication of curative radiotherapy. This standardized
      geriatric assessment will collect social information, functional, sensory, cognitive,
      emotional, motor, nutritional, and medical related to comorbidities . The quality of life of
      patients will be evaluated by the QLQ C30 (Quality of Life Questionnaire) European
      Organisation for Research and Treatment of Cancer (EORTC) before starting treatment, at the
      end of radiotherapy (2 months) and at 6 months. This short follow-up period seems appropriate
      in this elderly population and will allow an answer within 2 years to the problem raised in
      clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General tolerance of the radiotherapy evaluated by the QLQ-C30 questionnaire</measure>
    <time_frame>2 months</time_frame>
    <description>Tolerance will be called bad for the loss of 20 or more points (out of 100) between the initial assessment and evaluations at 2 and 6 months. Tolerance will be called correct in other cases. This threshold of 20 points was selected according to the work of Osoba.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete geriatric assessment</measure>
    <time_frame>6 months</time_frame>
    <description>This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General tolerance of the radiotherapy evaluated by the QLQ-C30 questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Tolerance will be called bad for the loss of 20 or more points (out of 100) between the initial assessment and evaluations at 2 and 6 months. Tolerance will be called correct in other cases. This threshold of 20 points was selected according to the work of Osoba.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>geriatric assessment and quality of life</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Included patient must have a geriatric assessment before radiotherapy and 6 months later.
Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>geriatric assessment and quality of life</intervention_name>
    <description>Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .
Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later.</description>
    <arm_group_label>geriatric assessment and quality of life</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>standard radiotherapy</description>
    <arm_group_label>geriatric assessment and quality of life</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Man with a histologically proven prostate cancer

          2. Indication of a curative intent radiotherapy

          3. Age ≥ 75 years

          4. Patient who signed an informed consent

        Exclusion Criteria:

          1. Patient with metastatic prostate cancer

          2. Patient unable to submit to monitoring of the protocol for social, geographical or
             family reasons

          3. A person who is not affiliated to a social security scheme or of such a scheme

          4. Patient under trusteeship
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurore GOINEAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancerologie de l'Ouest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphane SUPIOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François PEIN, MD</last_name>
    <email>francois.pein@ico.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurore GOINEAU, MD</last_name>
      <email>aurore.goineau@ico.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphane SUPIOT, MD</last_name>
      <email>stephane.supiot@ico.unicancer.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazid BELKACEMI, MD</last_name>
      <email>yazid.belkacemi@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne MARTIN, MD</last_name>
      <email>emartin@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth DENIAUD-ALEXANDRE, MD</last_name>
      <email>elisabeth.deniaud@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume BERA, MD</last_name>
      <email>g.bera@ch-bretagne-sud.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier BUTAHAUD, MD</last_name>
      <email>buthaud.xavier@catherinedesienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine de Radiologie</name>
      <address>
        <city>St Brieuc</city>
        <zip>22015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte VIE, MD</last_name>
      <email>b.vie@cario-sante.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHP</name>
      <address>
        <city>St Gregoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier ARTIGNAN, MD</last_name>
      <email>xartignan@vivalto-sante.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Mutualiste de l'Estuaire</name>
      <address>
        <city>St Nazaire</city>
        <zip>44606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BERGEROT, MD</last_name>
      <email>philippe.bergerot@mla.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Loire</name>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, MD</last_name>
      <email>Nicolas.Magne@icloire.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

